Key takeaway
What This Development Means
The FDA will require ICH E2B(R3) data standards for electronic safety reporting from October 2026. The change enhances data quality and global harmonisation but requires significant system upgrades. Stakeholders across the pharmaceutical value chain must act early to ensure compliance and avoid regulatory risk.
What are ICH E2B(R3) data standards?
ICH E2B(R3) data standards define the format and structure for electronic transmission of individual case safety reports. They improve data consistency, enable better signal detection, and align global pharmacovigilance practices, making safety reporting more efficient and interoperable across regulatory systems.
Who must comply with the FDA’s E2B(R3) requirement?
All organisations submitting postmarketing ICSRs electronically to the FDA via ESG NextGen must comply. This includes pharmaceutical companies, biotech firms, and other entities responsible for safety reporting of drugs, biologics, and combination products.
The US Food and Drug Administration (FDA) has confirmed that ICH E2B(R3) data standards will become mandatory for postmarketing individual case safety reports (ICSRs) submitted electronically from 1 October 2026. The requirement applies to human drug products, biological products, and combination products submitted via the FDA Adverse Event Monitoring System (AEMS), significantly impacting pharmacovigilance systems and regulatory compliance across the life sciences sector.
Shift To Harmonised Pharmacovigilance Standards
The move aligns US reporting requirements with internationally harmonised guidelines developed by the International Council for Harmonisation (ICH). The updated framework replaces the older E2B(R2) format, which will no longer be accepted after 30 September 2026. The FDA began accepting E2B(R3)-formatted submissions in January 2024, offering a transition period to allow companies to upgrade systems. However, from October 2026, all submissions through the Electronic Submissions Gateway NextGen must comply with the new structure.Key Changes In ICH E2B(R3) Data Standards
The revised standard introduces expanded and more granular data elements. Notably, it shifts the assessment of seriousness from the case level to the event level and enables embedded attachments within reports rather than separate submissions. These updates are designed to improve data quality, consistency, and analytical capability within AEMS. For regulators and companies alike, this enhances signal detection and supports more robust safety evaluations.Implications For Industry Stakeholders
The transition has broad implications beyond pharmaceutical manufacturers. Contract research organisations, pharmacovigilance service providers, IT vendors, and regulatory consultants must all ensure system readiness and compatibility. Companies that submit ICSRs electronically will need to validate updated reporting systems, retrain staff, and ensure data mapping aligns with the new schema. Once a company transitions to E2B(R3), all subsequent submissions must follow the same format. Smaller organisations that lack technical capability may continue to use the FDA Safety Reporting Portal, which remains an alternative submission route. However, this does not remove the broader industry shift towards structured, standardised data exchange.Compliance Timelines And Regulatory Risk
Failure to comply by the October 2026 deadline could result in rejected submissions or regulatory scrutiny. Given the role of ICSRs in postmarketing safety surveillance, non-compliance may also introduce reputational and operational risks.Related Articles
US Customs updates Section 232 pharmaceutical import filing rules as global duties expand
US Customs and Border Protection has issued updated entry guidance for Section 232 duties on patented pharmaceuticals and ingredients. Coverage expanded to products of companies outside Annex III from 29 September 2026. Importers must select among HTSUS headings 9903.04.60 to 9903.04.70, applying origin, patent status, use and onshoring conditions accurately.
European Medicines Agency Recommends Tighter Ipidacrine Medicine Restrictions
EMA recommends narrower ipidacrine uses, specialist prescribing and caution above 80 mg daily, pending a binding EU decision.
Japan MHLW Proposes Post-Market Plans For Designated Pharmacy Medicines
Japan proposes post-market plans for designated pharmacy medicines from May 2027, with consultation open until 10 October.
